ESMO 2018: ESMO Colloquia

The ESMO Colloquia are innovative new sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

Resources from ESMO Colloquium Sessions on OncologyPRO

(Restricted to ESMO Members)

Saturday, 20 October 2018

ESMO Colloquium: Hepatocellular carcinoma (HCC) treatment: Now, next and beyond

Hepatocellular carcinoma treatment thumb

Room: ICM – Room 1, 13:00-14:30
This educational activity is provided by ESMO and supported by Eisai.
View the ESMO colloquium details

Learning Objectives

  • To enhance understanding of loco-regional therapy (LRT) options and the evidence base to support the optimal outcomes
  • To inspire debate regarding what the optimal transition is from LRT to first line systemic treatment for HCC
  • To present the first line systemic treatment options and the rationale to move beyond monotherapy in a first line setting

Saturday, 20 October 2018

ESMO Colloquium: Systemic therapies in unresectable hepatocellular carcinoma (HCC): 1st and later lines

Systemic therapies in unresectable hepatocellular carcinoma thumb

Room: ICM – Room 14B, 18:30-20:00
This educational activity is provided by ESMO and supported by IPSEN.
View the ESMO colloquium details

Learning Objectives

  • To better understand the biology of HCC and the potential targets to be used
  • To review the efficacy of targeted agents in unresectable HCC
  • To get an update on the present potential role of immune checkpoints inhibitors
  • To overview the possible future treatment strategies with new agents or combined modalities

Sunday, 21 October 2018

ESMO Colloquium: Immune checkpoint inhibitors: Are we ready for combination?

Immune checkpoint inhibitors thumb

Room: Hall B3 – Room 22, 13:00-14:30
This educational activity is provided by ESMO and supported by Celgene.
View the ESMO colloquium details

Learning Objectives

  • To look at different ways of combining immune checkpoints inhibitors with same or different classes of treatment
  • To consider the potential adverse events
  • To review the present data in lung and breast cancer
  • To understand the role of potential predictive factors
  • To put in perspective the magnitude of clinical benefit compared to other alternatives

Sunday, 21 October 2018

ESMO Colloquium: Acute myeloid leukaemia: Focus on FLT3-ITD mutation

Acute myeloid leukaemia thumb

Room: Hall A1 – Room 15, 18:30-20:00
This educational activity is provided by ESMO and supported by Daiichi Sankyo.
View the ESMO colloquium details

Learning Objectives

  • To dissect acute myeloid leukemias from a molecular alteration point of view
  • To put the present molecular characterization in perspective with guidelines
  • To address the specificities of FTL3-ITD mutated subtype
  • To review the present achievements with the use of molecular targeted approaches

Sunday, 21 October 2018

ESMO Colloquium: Are Biosimilars the key to access, in practice?

Are Biosimilars the key to access thumb

Room: Hall A1– Room 16, 18:30-20:00
This educational activity is provided by ESMO and supported by Amgen, MSD, Pfizer and Sandoz.
View the ESMO colloquium details

Learning Objectives

  • Build confidence around the use of biosimilars in oncology, by providing examples of existing biosimilar use in supportive care (eg. Growth factors & epoetins)
  • Understand the concerns patients may have while getting switched from an originator to a biosimilar
  • Inform the healthcare community about the existing challenges for the uptake of oncology biosimilars following the recent survey conducted by ESMO about modulating the efficacy of immunotherapy
  • Assess the financial impact of oncology biosimilars on healthcare systems